Policy & Advocacy
Ethics & Compliance
MOPI Code of Ethics
The MOPI Code of Ethics for Sales and Marketing Practices of Prescription Products sets out standards to guide interactions between pharmaceutical companies and healthcare professionals, ensuring that such interactions are appropriate, ethical, transparent, and professional.
Patient and Healthcare Focus
Practices are guided by patient interests and responsible engagement with healthcare professionals.
Accountability
Members are responsible for upholding the Code and are subject to a transparent complaints and adjudication framework.
Transparency
Product information should be accurate, fair, and balanced to support informed prescribing decisions.
Independence
Healthcare professionals’ prescribing decisions must remain free from improper influence.
Legitimate Intent
Interactions should be conducted for proper reasons, in accordance with the law and the spirit of the Code.
Integrity
Members are expected to act ethically, honestly, and respectfully in their engagements.
Through the Code, MOPI reinforces responsible conduct, fair competition, and ethical engagement across the local pharmaceutical manufacturing industry.
Through the Code and its accompanying complaints and adjudication framework, MOPI reinforces a culture of responsible conduct, fair competition, and public trust in the local pharmaceutical manufacturing industry. The Code is aligned with relevant Malaysian laws and internationally recognised best practices.
MOPI Competition Policy
MOPI members participate in industry discussions in accordance with Malaysia’s Competition Act 2010 (Act 712), which prohibits anti-competitive agreements and abuse of dominant position.
Industry Advocacy
MOPI serves as the voice of the industry, engaging stakeholders on policies that support access to quality and affordable medicines.
Collective Industry Discussion
MOPI’s Executive Committee and members meet to discuss industry-wide challenges and strategies to support the development of the local pharmaceutical manufacturing industry.
Competition Law Compliance
All participants are required to comply with Malaysia’s Competition Act 2010 (Act 712), including avoiding discussions that may restrict competition or involve commercially sensitive information.
Meeting Reminders
For every MOPI meeting, the Secretariat reminds participants of the Competition Policy, including:
- The purpose of meetings is to discuss industry issues and policy matters through proper advocacy and communication.
- Participants should avoid discussion of individual company business practices or future plans, including prices, rebates, promotional activities, payment terms, or other commercial information.
- Participants should raise concerns if any discussion appears inconsistent with the Competition Policy.
Stronger Together.
Shaping the
Industry as One.
Join 60 pharmaceutical manufacturers shaping Malaysia’s regulatory landscape, accessing exclusive industry insights, and building expertise through GMP training and peer networks.